Retrophin (NASDAQ:RTRX) Rating Lowered to Strong Sell at BidaskClub

Retrophin (NASDAQ:RTRX) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Saturday, June 29th, BidAskClub reports.

Other analysts also recently issued research reports about the stock. Barclays started coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They set an “overweight” rating and a $55.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Retrophin in a report on Wednesday, April 17th. Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Finally, ValuEngine cut shares of Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $44.50.

NASDAQ RTRX traded down $0.18 during trading on Friday, hitting $21.21. The company had a trading volume of 590,475 shares, compared to its average volume of 421,098. The firm has a market capitalization of $878.88 million, a P/E ratio of -8.35 and a beta of 0.93. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69. Retrophin has a one year low of $17.53 and a one year high of $33.00. The stock has a fifty day simple moving average of $20.00.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.41). The firm had revenue of $39.57 million for the quarter, compared to the consensus estimate of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.14) earnings per share. As a group, equities research analysts expect that Retrophin will post -3.02 EPS for the current fiscal year.

In other Retrophin news, CFO Laura Clague sold 2,500 shares of Retrophin stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $18.25, for a total transaction of $45,625.00. Following the completion of the transaction, the chief financial officer now directly owns 14,750 shares of the company’s stock, valued at $269,187.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Neil F. Mcfarlane sold 1,968 shares of Retrophin stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $35,916.00. Following the transaction, the chief operating officer now directly owns 27,972 shares of the company’s stock, valued at $510,489. The disclosure for this sale can be found here. Insiders sold 10,819 shares of company stock worth $194,503 in the last 90 days. 4.32% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. lifted its stake in Retrophin by 17.6% in the fourth quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock worth $51,278,000 after acquiring an additional 339,588 shares during the period. Northern Trust Corp increased its holdings in shares of Retrophin by 0.6% during the fourth quarter. Northern Trust Corp now owns 760,496 shares of the biopharmaceutical company’s stock valued at $17,210,000 after acquiring an additional 4,277 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Retrophin by 30.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 777,520 shares of the biopharmaceutical company’s stock valued at $17,595,000 after acquiring an additional 182,318 shares in the last quarter. Perceptive Advisors LLC increased its holdings in shares of Retrophin by 4.0% during the fourth quarter. Perceptive Advisors LLC now owns 3,342,038 shares of the biopharmaceutical company’s stock valued at $49,782,000 after acquiring an additional 129,167 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Retrophin during the first quarter valued at about $143,000.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Further Reading: What is a recession?

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.